229 related articles for article (PubMed ID: 19153039)
1. Nitric oxide delivery to cancer: why and how?
Sonveaux P; Jordan BF; Gallez B; Feron O
Eur J Cancer; 2009 May; 45(8):1352-69. PubMed ID: 19153039
[TBL] [Abstract][Full Text] [Related]
2. Hypoxic tumor cell radiosensitization: role of the iNOS/NO pathway.
De Ridder M; Van Esch G; Engels B; Verovski V; Storme G
Bull Cancer; 2008 Mar; 95(3):282-91. PubMed ID: 18390408
[TBL] [Abstract][Full Text] [Related]
3. Nitric oxide: role in tumour biology and iNOS/NO-based anticancer therapies.
Singh S; Gupta AK
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1211-24. PubMed ID: 21544630
[TBL] [Abstract][Full Text] [Related]
4. [Vascularization and perfusion of tumors as target in cancer therapy].
Bernsen HJ; van der Kogel AJ; van Daal WA; Rijken PF
Ned Tijdschr Geneeskd; 1997 Feb; 141(8):364-8. PubMed ID: 9157295
[TBL] [Abstract][Full Text] [Related]
5. From pollutant gas to biological messenger: the diverse actions of nitric oxide in cancer.
Brennan PA; Moncada S
Ann R Coll Surg Engl; 2002 Mar; 84(2):75-8. PubMed ID: 11995767
[TBL] [Abstract][Full Text] [Related]
6. Optimization of tumor radiotherapy with modulators of cell metabolism: toward clinical applications.
Danhier P; De Saedeleer CJ; Karroum O; De Preter G; Porporato PE; Jordan BF; Gallez B; Sonveaux P
Semin Radiat Oncol; 2013 Oct; 23(4):262-72. PubMed ID: 24012340
[TBL] [Abstract][Full Text] [Related]
7. Tumour angiogenesis and response to radiotherapy.
Koukourakis MI
Anticancer Res; 2001; 21(6B):4285-300. PubMed ID: 11908683
[TBL] [Abstract][Full Text] [Related]
8. [Angiogenesis and radiotherapy (vessels, anaemia, oxygen and radiosensitivity)].
Lartigau E
Bull Cancer; 2007 Jul; 94 Spec No():S197-202. PubMed ID: 17846005
[TBL] [Abstract][Full Text] [Related]
9. Provascular strategy: targeting functional adaptations of mature blood vessels in tumors to selectively influence the tumor vascular reactivity and improve cancer treatment.
Sonveaux P
Radiother Oncol; 2008 Mar; 86(3):300-13. PubMed ID: 18313779
[TBL] [Abstract][Full Text] [Related]
10. Chemical radiosensitizers for use in radiotherapy.
Wardman P
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):397-417. PubMed ID: 17478086
[TBL] [Abstract][Full Text] [Related]
11. Targeting nitric oxide for cancer therapy.
Hirst D; Robson T
J Pharm Pharmacol; 2007 Jan; 59(1):3-13. PubMed ID: 17227615
[TBL] [Abstract][Full Text] [Related]
12. Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers.
Bischoff P; Altmeyer A; Dumont F
Expert Opin Ther Pat; 2009 May; 19(5):643-62. PubMed ID: 19441939
[TBL] [Abstract][Full Text] [Related]
13. Radiosensitising agents for the radiotherapy of cancer: novel molecularly targeted approaches.
Dumont F; Altmeyer A; Bischoff P
Expert Opin Ther Pat; 2009 Jun; 19(6):775-99. PubMed ID: 19456277
[TBL] [Abstract][Full Text] [Related]
14. Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy.
Ning S; Bednarski M; Oronsky B; Scicinski J; Knox SJ
Biochem Biophys Res Commun; 2014 May; 447(3):537-42. PubMed ID: 24735538
[TBL] [Abstract][Full Text] [Related]
15. [Anemia and radiotherapy].
Pasquier D; Lartigau E
Bull Cancer; 2003 Apr; 90 Spec No():S152-7. PubMed ID: 12856427
[TBL] [Abstract][Full Text] [Related]
16. The hypoxic tumour microenvironment, patient selection and hypoxia-modifying treatments.
Hoogsteen IJ; Marres HA; van der Kogel AJ; Kaanders JH
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):385-96. PubMed ID: 17433637
[TBL] [Abstract][Full Text] [Related]
17. NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001.
Scicinski J; Oronsky B; Ning S; Knox S; Peehl D; Kim MM; Langecker P; Fanger G
Redox Biol; 2015 Dec; 6():1-8. PubMed ID: 26164533
[TBL] [Abstract][Full Text] [Related]
18. Physiologic mechanisms of therapeutic resistance. Blood flow and hypoxia.
Teicher BA
Hematol Oncol Clin North Am; 1995 Apr; 9(2):475-506. PubMed ID: 7642474
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenics and radiotherapy.
Shannon AM; Williams KJ
J Pharm Pharmacol; 2008 Aug; 60(8):1029-36. PubMed ID: 18644195
[TBL] [Abstract][Full Text] [Related]
20. Vascular caveolin deficiency supports the angiogenic effects of nitrite, a major end product of nitric oxide metabolism in tumors.
Frérart F; Lobysheva I; Gallez B; Dessy C; Feron O
Mol Cancer Res; 2009 Jul; 7(7):1056-63. PubMed ID: 19567781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
